DFTX

$33.27+9.58%visit website

Definium Therapeutics, Inc.

Market Cap

$4.5B

Live price × SEC shares (Jul 30, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

2.24

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

4.9

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	30,978	33,521	41,484	48,665	154,648
Total operating expenses	45,669	47,578	59,220	75,077	227,544
Operating income	(45,669)	(47,578)	(59,220)	(75,077)	(227,544)
Interest expense	1,274	1,268	1,245	1,233	5,020
Net income	(67,265)	(50,436)	(77,098)	(158,986)	(353,785)
EPS (basic) ($)	(0.78)		(0.71)	(1.44)	(3.43)
EPS (diluted) ($)	(0.78)		(0.71)	(1.44)	(3.40)
Weighted avg. shares (basic)	85,886		108,791	110,685
Weighted avg. shares (diluted)	85,886		108,791	110,685

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 6, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 18 more quarters, back to Mar 2021, with Tormere Pro.

Signals

purchases / sales, 90d

Short Volume

70%

W/W +17.5pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

5.96x

Avg Daily Selling (90d)

911 sh/day

Baseline Daily Selling

413 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-09-25	2026-09-29	Barrow Robert	Director & Chief Executive Officer	Sale	31.6K	$36.57	$1.15M	2.21M	View
2026-09-25	2026-09-29	Wiley Matthew T.	Chief Commercial Officer	Sale	3,097	$36.57	$113K	359.0K	View
2026-09-25	2026-09-29	Sullivan Mark	Chief Legal Officer	Sale	14.1K	$36.57	$514K	494.2K	View
2026-09-25	2026-09-29	Roberts Brandi	Chief Financial Officer	Sale	3,377	$36.57	$123K	394.5K	View
2026-09-25	2026-09-29	Karlin Daniel	Director & Chief Medical Officer	Sale	10.9K	$36.57	$397K	792.8K	View

1–5 of 14

1 / 3

Recent News

Definium Therapeutics (DFTX) Posts Positive Phase 3 Data, Is The Pullback Making It Cheap?

Simply Wall St · 2026-11-06

Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress

Yahoo · 2026-11-04

Definium Therapeutics to Participate at Upcoming Investor Conferences

Yahoo · 2026-11-03

Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026

Yahoo · 2026-10-29

'New Bill In Congress Would Dramatically Overhaul How The Federal Government Classifies Drugs While Legalizing Marijuana' - Marijuana Moment

Benzinga · 2026-10-29

Compass Pathways: A Compelling Opportunity In A Large And Underserved Market

SeekingAlpha · 2026-10-28

Definium Therapeutics Announces New Employee Inducement Grants

Yahoo · 2026-10-26

Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales

SeekingAlpha · 2026-10-21

Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value

Yahoo · 2026-10-19

Definium Therapeutics: Outstanding Phase III Data De-Risks Pipeline, But Patience Required Ahead Of 2027

SeekingAlpha · 2026-10-13

JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84

Benzinga · 2026-10-09

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression

Yahoo Finance · 2026-09-24

Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching

Yahoo Finance · 2026-09-20

Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study

Yahoo Finance · 2026-09-19

Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results

Yahoo Finance · 2026-09-15

Informational purposes only, not investment advice.

DFTX

Financial Statements

Signals

Factor Profile

Recent News

Definium Therapeutics, Inc. (DFTX)

Reporting Insiders

Factor Profile

Date	Insider	Type	Shares	Value
2026-09-25	Barrow Robert	S	31,550	$1M
2026-09-25	Wiley Matthew T.	S	3,097	$113,257.29
2026-09-25	Sullivan Mark	S	14,051	$513,845.07
2026-09-25	Roberts Brandi	S	3,377	$123,496.89
2026-09-25	Karlin Daniel	S	10,853	$396,894.21